The EPICC platform presents a novel opportunity to modify disease progression through moderation of the most robust components of both humoral (complement system) and cellular (neutrophils) components of innate inflammatory responses.
EPICC molecules rapidly and dose dependently inhibit C1 and MBL, the earliest initiators of the classical and lectin complement pathway. Inhibition is via transformational changes of serine proteases at C1 and MBL.Learn More
In addition to complement modulation, the EPICC platform acts as a potent inhibitor of innate, neutrophil-mediated, inflammatory processes.Learn More
Hypoxic-ischemic encephalopathy (HIE) is a type of newborn brain damage caused by oxygen deprivation and limited blood flow.Learn More
Acute lung injury (ALI) is the pulmonary manifestation of an acute systemic inflammatory process characterized clinically by pulmonary infiltrates, hypoxemia and edema.Learn More
Platelet Refractoriness is common in cancer patients who receive frequent platelet transfusions and increases the risk of life-threatening hemorrhage.Learn More
Number of peer-reviewed publications and index studies on RLS-0071
Patents and patent applications active in: US, Europe (including many EU countries), Australia, Canada, Japan, China, UAE, South Korea, Mexico, Singapore, Saudi Arabia, Israel, Kuwait, India, South Africa.
Number of engineered peptides with potential for treating conditions in many therapeutic areas through its unique dual targeting mechanism.